The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin

Digestive Diseases

Volumn 34, Issue 3, 2016, Pages 269-278

  Ponziani, Francesca Romana ^a   Scaldaferri, Franco ^a   Petito, Valentina ^a   Paroni Sterbini, Francesco ^a   Pecere, Silvia ^a   Lopetuso, Loris R ^a   Palladini, Alessandra ^a   Gerardi, Viviana ^a   Masucci, Luca ^a   Pompili, Maurizio ^a   Cammarota, Giovanni ^a   Sanguinetti, Maurizio ^a   Gasbarrini, Antonio ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

Author keywords

Antibiotic; Eubiotic; Gut microbiota; Lactobacillus; Rifaximin

Indexed keywords

RIFAXIMIN; ANTIINFECTIVE AGENT; BACTERIAL DNA; RIFAMYCIN;

BACTERIAL GROWTH; BACTERIUM CULTURE; BIFIDOBACTERIACEAE; DNA ISOLATION; DRUG EFFECT; ECOLOGY; GASTROINTESTINAL DISEASE; HUMAN; INTESTINE FLORA; LACTOBACILLUS; LIVER DISEASE; METAGENOMICS; MICROBIAL COMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW; DRUG EFFECTS; ISOLATION AND PURIFICATION;

ANTI-BACTERIAL AGENTS; DNA, BACTERIAL; GASTROINTESTINAL MICROBIOME; HUMANS; LACTOBACILLUS; RIFAMYCINS;

EID: 84971654716     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000443361     Document Type: Review

References (49)

1. Gophna U, Sommerfeld K, Gophna S, Doolittle WF, Veldhuyzen van Zanten SJ: Differences between tissue-associated intestinal microfloras of patients with Crohn's disease and ulcerative colitis. J Clin Microbiol 2006; 44: 4136-4141.
2. Vijay-Kumar M, Aitken JD, Carvalho FA, Cullender TC, Mwangi S, Srinivasan S, et al: Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 2010; 328: 228-231.
3. Carvalho FA, Koren O, Goodrich JK, Johansson ME, Nalbantoglu I, Aitken JD, et al: Transient inability to manage proteobacteria promotes chronic gut inflammation in TLR5-deficient mice. Cell Host Microbe 2012; 12: 139-152.
4. Cullender TC, Chassaing B, Janzon A, Kumar K, Muller CE, Werner JJ, et al: Innate and adaptive immunity interact to quench microbiome flagellar motility in the gut. Cell Host Microbe 2013; 14: 571-581.
5. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz N, Pace NR, et al: Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U S A 2007; 104: 13780-13785.
6. Carroll IM, Chang YH, Park J, Sartor RB, Ringel Y: Luminal and mucosal-associated intestinal microbiota in patients with diarrheapredominant irritable bowel syndrome. Gut Pathog 2010; 2: 19.
7. Krogius-Kurikka L, Lyra A, Malinen E, Aarnikunnas J, Tuimala J, Paulin L, et al: Microbial community analysis reveals high level phylogenetic alterations in the overall gastrointestinal microbiota of diarrhoea-predominant irritable bowel syndrome sufferers. BMC Gastroenterol 2009; 9: 95.
8. Salonen A, de Vos WM, Palva A: Gastrointestinal microbiota in irritable bowel syndrome: present state and perspectives. Microbiology 2010; 156: 3205-3215.
9. Daniels L, Philipszoon LE, Boermeester MA: A hypothesis: important role for gut microbiota in the etiopathogenesis of diverticular disease. Dis Colon Rectum 2014; 57: 539-543.
10. Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, et al: Altered profile of human gut microbiome is associated with cirrhosis and its complications. J Hepatol 2014; 60: 940-947.
11. Bajaj JS, Hylemon PB, Ridlon JM, Heuman DM, Daita K, White MB, et al: Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012; 303:G675-G685.
12. Ubeda C, Taur Y, Jenq RR, Equinda MJ, Son T, Samstein M, et al: Vancomycin-resistant enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120: 4332-4341.
13. Cho I, Blaser MJ: The human microbiome: At the interface of health and disease. Nat Rev Genet 2012; 13: 260-270.
14. Buffie CG, Jarchum I, Equinda M, Lipuma L, Gobourne A, Viale A, et al: Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 2012; 80: 62-73.
15. Prantera C, Lochs H, Campieri M, Scribano ML, Sturniolo GC, Castiglione F, et al: Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin. Aliment Pharmacol Ther 2006; 23: 1117-1125.
16. Shafran I, Johnson LK: An open-label evaluation of rifaximin in the treatment of active Crohn's disease. Curr Med Res Opin 2005; 21: 1165-1169.
17. Shafran I, Burgunder P: Rifaximin for the treatment of newly diagnosed Crohn's disease: A case series. Am J Gastroenterol 2008; 103: 2158-2160.
18. Campieri M, Rizzello F, Venturi A, et al: Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: A randomized controlled study versus mesalazine. Gastroenterology 2000; 118:A781.
19. Prantera C, Lochs H, Grimaldi M, Danese S, Scribano ML, Gionchetti P; Retic Study Group (Rifaximin-Eir Treatment in Crohn's Disease): Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. Gastroenterology 2012; 142: 473-481.
20. Guslandi M, Petrone MC, Testoni PA: Rifaximin for active ulcerative colitis. Inflamm Bowel Dis 2006; 12: 335.
21. Gionchetti P, Rizzello F, Ferrieri A, Venturi A, Brignola C, Ferretti M, et al: Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: A double-blind, placebo-controlled trial. Dig Dis Sci 1999; 44: 1220-1221.
22. Papi C, Ciaco A, Koch M, Capurso L: Efficacy of rifaximin in the treatment of symptomatic diverticular disease of the colon. A multicentre double-blind placebo-controlled trial. Aliment Pharmacol Ther 1995; 9: 33-39.
23. Latella G, Pimpo MT, Sottili S, Zippi M, Viscido A, Chiaramonte M, et al: Rifaximin improves symptoms of acquired uncomplicated diverticular disease of the colon. Int J Colorectal Dis 2003; 18: 55-62.
24. Colecchia A, Vestito A, Pasqui F, Mazzella G, Roda E, Pistoia F, et al: Efficacy of long term cyclic administration of the poorly absorbed antibiotic rifaximin in symptomatic, uncomplicated colonic diverticular disease. World J Gastroenterol 2007; 13: 264-269.
25. Pimentel M, Lembo A, Chey WD, Zakko S, Ringel Y, Yu J, et al: Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med 2011; 364: 22-32.
26. Marchese A, Salerno A, Pesce A, Debbia EA, Schito GC: In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species. Chemotherapy 2000; 46: 253-266.
27. Jiang ZD, Ke S, DuPont HL: Rifaximin-induced alteration of virulence of diarrhoeaproducing Escherichia coli and Shigella sonnei. Int J Antimicrob Agents 2010; 35: 278-281.
28. Brown EL, et al: Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob Agents Chemother 2010; 54: 388-396.
29. Hirota SA: Understanding the molecular mechanisms of rifaximin in the treatment of gastrointestinal disorders-a focus on the modulation of host tissue function. Mini Rev Med Chem 2015; 16: 206-217.
30. Maccaferri S, Vitali B, Klinder A, Kolida S, Ndagijimana M, Laghi L, et al: Rifaximin modulates the colonic microbiota of patients with Crohn's disease: An in vitro approach using a continuous culture colonic model system. Antimicrob Chemother 2010; 65: 2556-2565.
31. Xu D, Gao J, Gillilland M 3rd, Wu X, Song I, Kao JY, et al: Rifaximin alters intestinal bacteria and prevents stress-induced gut inflammation and visceral hyperalgesia in rats. Gastroenterology 2014; 146: 484-496.
32. Brigidi P, Swennen E, Rizzello F, Bozzolasco M, Matteuzzi D: Effects of rifaximin administration on the intestinal microbiota in patients with ulcerative colitis. J Chemother 2002; 14: 290-295.
33. Bajaj JS, Heuman DM, Sanyal AJ, Hylemon PB, Sterling RK, Stravitz RT, et al: Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLoS One 2013; 8:e60042.
34. Waldor MK, Tyson G, Borenstein E, Ochman H, Moeller A, Finlay BB, et al: Where next for microbiome research? PLoS Biol 2015; 13:e1002050.
35. http://www. eufic. org.
36. http://nut. entecra. it.
37. Calanni F, Renzulli C, Barbanti M, Viscomi GC: Rifaximin: Beyond the traditional antibiotic activity. J Antibiot (Tokyo) 2014; 67: 667-670.
38. Borruel N, Carol M, Casellas F, et al: Increased mucosal tumour necrosis factor alpha production in Crohn's disease can be downregulated ex vivo by probiotic bacteria. Gut 2002; 51: 659-664.
39. Thomas CM, Hong T, van Pijkeren JP, Hemarajata P, Trinh DV, Hu W, Britton RA, Kalkum M, Versalovic J: Histamine derived from probiotic Lactobacillus reuteri suppresses TNF via modulation of PKA and ERK signaling. PLoS One 2012; 7:e31951.
40. Llopis M, Antolin M, Carol M, et al: Lactobacillus casei downregulates commensals' inflammatory signals in Crohn's disease mucosa. Inflamm Bowel Dis 2009; 15: 275-283.
41. Ait-Belgnaoui A, Bradesi S, Fioramonti J, et al: Acute stress-induced hypersensitivity to colonic distension depends upon increase in paracellular permeability: role of myosin light chain kinase. Pain 2005; 113: 141-147.
42. Zareie M, Johnson-Henry K, Jury J, et al: Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. Gut 2006; 55: 1553-1560.
43. Morgun A, Dzutsev A, Dong X, Greer RL, Sexton DJ, Ravel J, et al: Uncovering effects of antibiotics on the host and microbiota using transkingdom gene networks. Gut 2015; 64: 1732-1743.
44. Cullen TW, Schofield WB, Barry NA: Gut microbiota. Antimicrobial peptide resistance mediates resilience of prominent gut commensals during inflammation. Science 2015; 347: 170-175.
45. Jiang ZD, Ke S, Palazzini E, Riopel L, Dupont H, et al: In vitro activity and fecal concentration of rifaximin after oral administration. Antimicrob Agents Chemother 2000; 44: 2205-2206.
46. Finegold SM, Molitoris D, Vaisanen ML: Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora. Antimicrob Agents Chemother 2009; 53: 281-286.
47. Kim MS, Morales W, Hani AA, et al: The effect of rifaximin on gut flora and Staphylococcus resistance. Dig Dis Sci 2013; 58: 1676-1682.
48. Dethlefsen L, Relman DA: Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 2011; 108(suppl 1):4554-4561.
49. Soldi S, Vasileiadis S, Uggeri F, Campanale M, Morelli L, Fogli MV, Calanni F, Grimaldi M, Gasbarrini A: Modulation of the gut microbiota composition by rifaximin in non-constipated irritable bowel syndrome patients: A molecular approach. Clin Exp Gastroenterol 2015;8:309-325.